Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals Inc (NQ: RYTM )

22.93 -0.20 (-0.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 405,782
Open 23.34
Bid (Size) 22.50 (4)
Ask (Size) 23.99 (1)
Prev. Close 23.13
Today's Range 22.38 - 23.34
52wk Range 15.50 - 34.99
Shares Outstanding 56,901,530
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-19.95%
-19.95%
1 Month
-11.86%
-11.86%
3 Month
+42.13%
+42.13%
6 Month
+23.25%
+23.25%
1 Year
-6.43%
-6.43%

More News

Read More
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) Near the Top of Equities by Percentage Gain on 8/1
Via Investor Brand Network
Rhythm Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Rhythm Pharmaceuticals Announces Update to September Conference Participation
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals to Present at Investor Conferences in September
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2023
Via Benzinga
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Caterpillar, Oshkosh, AudioCodes And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
What Will Amgen Buy Next?
Via The Motley Fool
Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.